Skip to main content
. 2020 Nov 13;10:19815. doi: 10.1038/s41598-020-76756-1

Figure 5.

Figure 5

Kaplan–Meier analyses of mCRC samples based on DpR. (A) OS in all patients receiving chemotherapy plus cetuximab or bevacizumab; (B) OS in patients with left-sided mCRCs receiving chemotherapy plus cetuximab; (C) OS in patients with left-sided mCRCs receiving chemotherapy plus bevacizumab; (D) OS in patients with right-sided mCRCs receiving chemotherapy plus cetuximab; and (E) OS in patients with right-sided mCRCs receiving chemotherapy plus bevacizumab. Median DpRs were calculated as -30 for A, -32 for B and C, and -27.5 for D and E, respectively. CI confidence interval, HR hazard ratio. Broken line, all population.